Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service aortic endografts (EVAR/TEVAR) cases in Virginia: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 10% on average (139 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 9 | 611 | 24% |
| 2020 | 3 | 472 | 28% |
| 2021 | 3 | 483 | 33% |
| 2022 | 5 | 450 | 37% |
| 2023 | 1 | 404 | 40% |
| 2024 | 3 | 443 | 42% |
| 2025 from claims | – | 412 333–484 | 43% |
| 2026 forecast | – | 419 328–526 | 44% |
| 2027 forecast | – | 424 314–560 | 44% |
| 2028 forecast | – | 429 303–592 | 45% |
| 2029 forecast | – | 433 295–621 | 46% |
| 2030 forecast | – | 438 287–650 | 46% |
Endovascular abdominal and thoracic aortic repair. Professional codes (what the surgeon bills): CPT 34701, 34702, 34703, 34704, 34705, 34706, 33880, 33881; the hospital bills MS-DRG 268, 269, 213, 209.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Virginia; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 10 | 1,226−4.3%/yr | −4.3%/yr | 0.6 | 0% | 1,210 in 2030−0.2%/yr |
| Texas | 3 | 1,065−5.8%/yr | −5.8%/yr | 0.5 | 0% | 1,150 in 2030+1.3%/yr |
| North Carolina | 3 | 449−8.3%/yr | −8.3%/yr | 0.5 | 0% | 420 in 2030−1.1%/yr |
| Georgia | 2 | 405−5.4%/yr | −5.4%/yr | 0.5 | 0% | 450 in 2030+1.8%/yr |
| Tennessee | 2 | 345−9.6%/yr | −9.6%/yr | 0.5 | 0% | 400 in 2030+2.4%/yr |
| Maryland | 2 | 330−2.9%/yr | −2.9%/yr | 0.4 | 0% | 400 in 2030+3.3%/yr |
| Kentucky | 2 | 285−10%/yr | −10%/yr | 0.6 | 0% | 280 in 2030−0.3%/yr |
| South Carolina | 0 | 274−8.3%/yr | −8.3%/yr | 0.4 | 0% | 250 in 2030−1.7%/yr |
| Alabama | 2 | 218−11%/yr | −11%/yr | 0.5 | 0% | 230 in 2030+1%/yr |
| Arkansas | 6 | 201−3.4%/yr | −3.4%/yr | 0.5 | 0% | 170 in 2030−3.1%/yr |
| Louisiana | 0 | 167−8.5%/yr | −8.5%/yr | 0.4 | 0% | 140 in 2030−2.8%/yr |
| Oklahoma | 3 | 167−14%/yr | −14%/yr | 0.3 | 0% | 190 in 2030+2.3%/yr |
| Mississippi | 2 | 121−7.9%/yr | −7.9%/yr | 0.3 | 0% | 130 in 2030+1.1%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Dialysis access | 50 | 5,185−16%/yr | −16%/yr | 5.10.9× | 61% | 5,340 in 2030+0.5%/yr |
| Superficial venous ablation | 57 | 3,844−3.8%/yr | −3.8%/yr | 3.50.6× | 94% | 4,330 in 2030+2%/yr |
| Peripheral arterial intervention | 30 | 3,751−7.6%/yr | −7.6%/yr | 3.50.5× | 43% | 5,530 in 2030+6.7%/yr |
| Carotid revascularization | 28 | 1,070−3.9%/yr | −3.9%/yr | 1.00.8× | 0% | 1,290 in 2030+3.1%/yr |
| Thrombectomy, IVC filters & venous stents | 4 | 1,041−5.6%/yr | −5.6%/yr | 1.00.6× | 2% | 1,720 in 2030+8.7%/yr |
Aortic endografts (EVAR/TEVAR) in every state, and its device makers · Every procedure market in Virginia · Every state · Compare with Florida
Medtronic leads with 76% of company spending on these surgeons in 2025, −5 pts on 2024.
In 2025, 5 companies reported engagement with Virginia’s surgeons worth $299K in consulting, speaking, meals and travel tied to these products, about $100K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 36 clearances and approvals in the category, 2 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.